Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

Nature medicine·2026

Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026

Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026

Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026

Same author

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Focused ultrasound-enhanced cell therapy for brain tumors: Summary of roundtable discussions.

Neuro-oncology advances·2026

Search research articles

Related Experiment Video

Updated: Feb 17, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Developing T-cell therapies for lymphoma without receptor engineering.

Melanie Grant¹, Catherine M Bollard^1,2

¹Center for Cancer and Immunology Research, Children's National Health System, Washington, DC; and.

Hematology. American Society of Hematology. Education Program

|December 10, 2017

Summary

This summary is machine-generated.

T-cell therapy shows promise for lymphoma treatment. Beyond engineered receptors, expanding antigen-specific T cells ex vivo improves patient responses and survival.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Feb 17, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

T-cell therapy is a rapidly advancing field for treating lymphoma.
Treatment efficacy depends on patient immune status and disease characteristics.
Existing T-cell therapies include engineered receptors and ex vivo expanded T cells.

Purpose of the Study:

To review T-cell therapeutics for lymphoma beyond receptor engineering.
To highlight alternative T-cell-based treatment strategies.

Main Methods:

Literature review of T-cell therapies for lymphoma.
Focus on ex vivo expansion of antigen-specific T cells.
Analysis of T-cell targeting viral and nonviral tumor-associated antigens.

Main Results:

Ex vivo expansion of antigen-specific T cells demonstrates clinical benefit.
These approaches enhance clinical responses in lymphoma patients.
Improved overall survival is observed with these T-cell therapeutics.

Conclusions:

T-cell therapy offers viable treatment options for lymphoma.
Strategies beyond receptor engineering are crucial for enhancing outcomes.
Further research into ex vivo expanded T cells is warranted.